Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia

Inclusion Criteria: * Diagnosis of Primary Fibromyalgia (2010 ACR criteria) * Male or female 18-75 years old * Patients currently receiving pharmacologic treatment for depression should have been clinically stable for at least 3 months prior to randomization, and on stable doses of antidepressants during this 3 month time frame. * Willing and able to withdraw specific therapies (ask PI) * If female, medically acceptable form of contraception or not of child bearing potential. * Provide written informed consent to participate. * Willing and able to comply with all protocol specified requirement. Exclusion Criteria: * Arthritis, lupus and other systemic auto-immune diseases * Regional or persistent pain that could interfere with assessment of fibromyalgia pain * Bipolar and psychotic disorders * Increased risk of suicide * Significant clinical (cardiac, systemic infection, systemic corticosteroid requirement, drug/alcohol abuse) or laboratory abnormalities. * Inability to wash-out specific medications (ask PI) * Known hypersensitivity to cyclobenzaprine * Others: seizure disorders, severe/untreated sleep apnea, BMI\>45